Product Information
RISPERIDONE ER 37.5 MG VIAL is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $566.4039 per EA under NDC 00480134208. Its NADAC has been published 120 times since Jun 19, 2024.
FDA first approved this application on Dec 5, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Risperidone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480134208
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA214068FDA Approved
12/5/2023
TE Code
AB
On Market Since
12/11/2023
Price Statistics
The NADAC for RISPERIDONE ER 37.5 MG VIAL has been published 120 times since Jun 19, 2024, and over the history we have for it it has declined 20.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $566.4039 per EA |
|---|---|
| All-time high | $732.9669 (Aug 13, 2025) |
| All-time low | $554.8895 (Jul 22, 2026) |
| 52-week high | $729.8571 |
| 52-week low | $554.8895 |
| Median price | $715.8185 |
| Average price | $698.4146 |
| Largest weekly change | -22.5% (Jun 17, 2026) |
| Weeks tracked | 120 |
| Tracking since | Jun 19, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 37% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Risperidone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RISPERIDONE ER 37.5 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for RISPERIDONE ER 37.5 MG VIAL, manufactured by Teva Pharmaceuticals USA Inc., is $566.4039 per EA (NDC 00480134208), effective Sep 30, 2026.
How has the price of RISPERIDONE ER 37.5 MG VIAL changed over time?
Over the history we have for it, the NADAC for RISPERIDONE ER 37.5 MG VIAL has declined 20.9%. It has been tracked across 120 weekly CMS publications since Jun 19, 2024.
What are the highest and lowest recorded NADAC prices for RISPERIDONE ER 37.5 MG VIAL?
Since Jun 19, 2024, the NADAC for RISPERIDONE ER 37.5 MG VIAL has ranged from a low of $554.8895 (Jul 22, 2026) to a high of $732.9669 (Aug 13, 2025), with a median of $715.8185 per EA.
Are there cheaper alternatives to RISPERIDONE ER 37.5 MG VIAL?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RISPERIDONE ER 25 MG VIAL, is $355.2316 per EA — about 37% below RISPERIDONE ER 37.5 MG VIAL.
Who manufactures RISPERIDONE ER 37.5 MG VIAL?
RISPERIDONE ER 37.5 MG VIAL (NDC 00480134208) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.